NASDAQ
Illumina, Inc. (ILMN)
♥ 333 Thanks from members
Illumina (ILMN) exhibits strong positive momentum driven by better-than-expected clinical growth, robust execution of the NovaSeq X and SomaLogic platforms, and an underwhelming product launch by competitor Roche, though tempered by ongoing China exposure and regulatory hurdles.